QuidelOrtho Corporation announced the U.S. Food and Drug Administration (FDA) approval of its Micro Typing Systems (MTS) DAT Card.
The MTS DAT Card completes QuidelOrtho's gel-based solution for direct antiglobulin testing. When paired with the ORTHO VISION Platform, it combines proven column agglutination technology with advanced software capabilities – including reflex testing and as-needed quality control – to help laboratories deliver faster, more reliable results for patients who depend on timely transfusion decisions.
QuidelOrtho also announced their upcoming participation at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting taking place October 25-28, 2025 in San Diego, CA..
Featured education sessions
- Sunday, 10:00–10:30 a.m. PT
Missing Formula: The Challenging World of Rh(D) Antigen
Sue T. Johnson, MSTM, MLS(ASCP)SBBCM
An in-depth look at the complexities of Rh(D) antigen identification and its implications for transfusion safety.
- Monday, 11:40 a.m.–12:10 p.m. PT
Identifying the Imposter: How ID-MTS Gel Test Typing Can Help Blood Banks with DARA Patients
Lehang Dingh, MLS(ASCP)SBBCM
Explore how gel testing can help distinguish true antibodies from drug interference in patients treated with daratumumab.
- Monday, 1:45–2:15 p.m. PT
Type & Seek: Solution to the Patient Puzzle
Shane Grimsley, DipRCPath, FBBTS, Senior Clinical Scientist, IBGRL
Learn strategies for resolving complex serological cases using advanced immunohematology techniques.
Poster presentations
- Evaluation of a Gel Card Being Designed for the Detection of IgG and C3
- Reliability of Instrumentation for Immunohematology Testing in the Transfusion Medicine Laboratory
These posters offer insights into performance and reliability metrics that support confident decision-making in the lab.
Product demonstrations
- ORTHO VISION Max Swift Analyzer
- ORTHO VISION Swift Analyzer
ORTHO CONNECT Lab Management Software
